01 · Identity
One molecule, several searchable names.
Daraxonrasib is the generic name; RMC-6236is the development code found throughout early research and clinical-trial records. RASONQUE is the U.S. brand name for the finished prescription medicine from Revolution Medicines.
02 · RAS(ON) mechanism
Targeting the active, GTP-bound state of RAS.
Peer-reviewed work describes daraxonrasib as a non-covalent, multi-selective RAS(ON) inhibitor. The molecule first binds cyclophilin A (CypA); that binary complex then engages active, GTP-bound RAS to form a tri-complex. The assembled complex sterically blocks interactions between RAS and downstream effector proteins.
binds CypA
engages RAS-GTP
blocks effector binding
This simplified research summary is not prescribing information and does not describe all pharmacology, safety, or clinical-use considerations.
Jiang et al., Cancer Discovery (2024)↗03 · Regulatory status
The science moved from development code to approved ingredient.
FDA approved daraxonrasib as RASONQUE.
The FDA approval notice identifies daraxonrasib (RASONQUE, Revolution Medicines, Inc.) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
Read the FDA approval notice↗Approval of a finished drug does not make bulk compound or research material interchangeable with the medicine. Patients and clinicians should use the official label and manufacturer channels; Daraxon does not provide medical advice or dispense RASONQUE.
04 · Daraxon research material
Defined for qualified R&D and registration workflows.
Daraxon’s offering is intended for professional organizations conducting chemical, analytical, formulation, nonclinical, process-development, or drug-registration work. A request should identify the intended use, quantity range, destination and documentation needs so suitability can be assessed before supply.
Not for personal purchase, self-administration, compounding, diagnosis, treatment, or any human use.
05 · Quality package
Batch evidence—not generic promises.
The target commercial specification is ≥99% purity by HPLC. The actual result, test methods and release decision must be taken from the Certificate of Analysis for the specific lot.
Certificate of Analysis
Identity, assay or purity, lot information and release data.
Chromatography
Batch-relevant HPLC documentation and method context where applicable.
Spectroscopy
NMR or other identity-supporting data available according to the supplied package.
Regulatory reference
Daraxon identifies its Type II U.S. Drug Master File as DMF 43871; verify current status directly with FDA.
06 · FAQ
Common daraxonrasib questions.
What is daraxonrasib?
Daraxonrasib is the nonproprietary name of a RAS GTPase-family inhibitor. It was developed as RMC-6236 and is the active ingredient in the FDA-approved prescription medicine RASONQUE.
Are daraxonrasib and RMC-6236 the same compound?
Yes. RMC-6236 is the development code used in scientific papers and trial records; daraxonrasib is the generic name.
Is Daraxon selling RASONQUE?
No. RASONQUE is a finished prescription medicine from Revolution Medicines. Daraxon describes research/API material for qualified organizations and is not affiliated with Revolution Medicines.
Can Daraxon material be used in people?
No. Daraxon material is offered only for qualified research, analytical, or drug-registration work and is not for personal, diagnostic, therapeutic, or human use.